PM506. Psilocybin Clinical Trial: Acute Effects and its relationship to the brain activity as measured by quantitative EEG

作者：Filip Tylš, Tomas Palenicek Michaela Viktorinova, Dominika Prokopcova, Jakub Korčák, R. Androvičová, M. Brunovský, Jiří Horáček · 发表于：International Journal of Neuropsychopharmacology · 年份：2016 · DOI：10.1093/ijnp/pyw041.506 · 被引用次数：9 · 研究领域：Medicine

Objective: Schizophrenia patients have a higher prevalence of type 2 diabetes mellitus than the general population, and even first-episode, drug-naive (FEDN) patients with schizophrenia have shown a higher prevalence of impaired glucose tolerance (IGT) than the general population. We aimed to investigate the prevalence of abnormal glucose tolerance after glucose loading, and to examine the relationship between IGT and clinical phenotypes or cognitive deficits in FEND patients with schizophrenia among a Han Chinese population. Method: 175 inpatients meeting DSM-IV schizophrenia criteria were compared with 31 healthy controls on anthropometric measures and fasting plasma levels of glucose, insulin and lipids. They were also compared using a 75-g oral glucose tolerance test (OGTT) and a homeostasis model assessment of insulin resistance (HOMA-IR). Neurocognitive functioning was assessed using the MATRICS Consensus Cognitive Battery (MCCB). Patient psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS). Results: Among the patients, 24.5% had IGT, compared to none of the healthy controls. Also, the patients had significantly higher levels of fasting glucose and two-hour glucose, and were more insulin resistant as measured with HOMA. Compared to those patients without IGT, the IGT patients were older, had a later age of schizophrenia onset, higher waist or hip circumference and BMI, higher levels of low-density lipoprotein and triglycerides and higher i...